The discovery of new spirocyclic muscarinic M3 antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 24, 2010, Pages 7458-7461

  Stocks, Michael J ^a   Alcaraz, Lilian ^a   Bailey, Andrew ^a   Bowers, Keith ^a   Donald, David ^a   Edwards, Helen ^a   Hunt, Fraser ^a   Kindon, Nicholas ^a   Pairaudeau, Garry ^a   Theaker, Jill ^a   Warner, Daniel J ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Antagonist; Muscarinic

Indexed keywords

ACLIDINIUM BROMIDE; GLYCOPYRROLATE BROMIDE; MUSCARINIC M3 RECEPTOR ANTAGONIST; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING;

ANIMALS; DRUG EVALUATION, PRECLINICAL; HEPATOCYTES; HUMANS; MICROSOMES; RATS; RECEPTOR, MUSCARINIC M3; SPIRO COMPOUNDS;

EID: 78449273352     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.10.016     Document Type: Article

References (21)

1. R.M. Eglen Prog. Med. Chem. 43 2005 105
2. I. Peretto, P. Petrillo, and B.P. Imbimbo Med. Res. Rev. 29 2009 867
3. Dramane I. Laine Expert Rev. Clin. Pharmacol. 3 2010 43
4. M. Cazzola, and M.G. Matera Br. J. Pharmacol. 155 2008 291
5. G.F. Joos Expert Opin. Invest. Drugs 19 2010 257
6. P. Casarosa, T. Bouyssou, S. Germeyer, A. Schnapp, F. Gantner, and M. Pieper J. Pharmacol. Exp. Ther. 330 2009 660
7. N.J. Gross Chest 126 2004 1946
8. A.R. ZuWallack, and R.L. ZuWallack Expert Opin. Pharmacol. 5 2004 1827
9. T.T. Hansel, H. Neighbour, E.M. Erin, A.J. Tan, R.C. Tennant, J.G. Maus, and P.J. Barnes Chest 128 2005 1974
10. A. Gavalda, M. Miralpeix, I. Ramos, R. Otal, C. Carreno, M. Vinals, T. Domenech, C. Carcasona, B. Reyes, D. Vilella, J. Gras, J. Cortijo, E. Morcillo, J. Llenas, H. Ryder, and J. Beleta J. Pharmacol. Exp. Ther. 331 2009 740
11. K.S. Naruganahalli Expert Opin. Invest. Drugs 16 2007 1127
12. A.M. Lee, D.B. Jacoby, and A.D. Fryer Curr. Opin. Pharmacol. 1 2001 223
13. For some recent examples see: Y. Sagara, T. Kimura, T. Fujikawa, K. Noguchi, and Norikazu. Ohtake Bioorg. Med. Chem. Lett. 13 2003 57
14. O. Diouf, S. Gadeau, F. Chelle, M. Gelbcke, P. Talaga, B. Christophe, M. Gillard, R. Massingham, and M. Guyaux Bioorg. Med. Chem. Lett. 12 2002 2535
15. A. Piergentili, W. Quaglia, F. Del Bello, M. Giannella, M. Pigini, E. Barocelli, S. Bertoni, R. Matucci, M. Nesi, B. Bruni, and M. Di Vaira Bioorg. Med. Chem. 17 2009 8174
16. D.I. Laine, Z. Wan, H. Yan, C. Zhu, H. Xie, W. Fu, J. Busch-Petersen, C. Neipp, R. Davis, K.L. Widdowson, F.E. Blaney, J. Foley, A.M. Bacon, E.F. Webb, M.A. Luttmann, M. Burman, H.M. Sarau, M. Salmon, M.R. Palovich, and K. Belmonte J. Med. Chem. 52 2009 5241
17. J. Jin, B. Budzik, Y. Wang, D. Shi, F. Wang, H. Xie, Z. Wan, C. Zhu, J.J. Foley, E.F. Webb, M. Berlanga, M. Burman, H.M. Sarau, D.M. Morrow, M.L. Moore, R.A. Rivero, M. Palovich, M. Salmon, K.E. Belmonte, and D.I. Laine J. Med. Chem. 51 2008 5915
18. J.-P. Starck, L. Provins, B. Christophe, M. Gillard, S. Jadot, P. Lo Brutto, L. Quere, P. Talaga, and M. Guyaux Bioorg. Med. Chem. Lett. 18 2008 2675
19. 3H]-NMS binding.
20. Pharmacophore modelling was performed using the Schrödinger software suite within Maestro (Maestro, version 9.0, Schrödinger, LLC, New York, NY, 2009). 3D conformations of the molecules were generated and ionisation states at pH 7.0 ± 1.0 were assigned by the small molecule preparation utility LigPrep (LigPrep, version 2.3, Schrödinger, LLC, New York, NY, 2009). Phase (Phase, version 3.1, Schrödinger, LLC, New York, NY, 2009) was used to identify a 4-point pharmacophore model that encompassed all three active ligands, using default parameters for both the identification of potential hypotheses and subsequent scoring of the candidates.
21. S. Sabbani, P.A. Stocks, G.L. Ellis, J. Davies, E. Hedenstrom, S.A. Ward, and P.M. O'Neill Bioorg. Med. Chem. Lett. 18 2008 5804